Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
Study Design
- Studientyp
- Review
- Intervention
- Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Finasteride 1 mg/day (androgenetic alopecia) or 5 mg/day (BPH); dutasteride 0.5 mg/day
- Vergleichsgruppe
- Placebo
- Wirkungsrichtung
- Negative
- Verzerrungsrisiko
- Unclear
Abstract
The 5-α-reductase inhibitors finasteride and dutasteride are frequently used in the treatment of androgenetic alopecia and benign prostatichyperplasia. These drugs are effective at reducing levels of dihydrotestosterone, the primary androgen responsible for the pathogenesis of both these conditions. However, finasteride and dutasteride have also been shown to produce an increase in the incidence of sexual dysfunction, namely, impotence, decreased libido, and ejaculation disorder. The purpose of this study is to review the existing medical literature with regard to the sexual side effects of 5-α-reductase inhibitor therapy. This review is an extensive look at the sexual effects of 5-α-reductase inhibitors and compares outcomes for finasteride versus dutasteride in addition to comparing sexualside effects for each of the different dosages prescribed of finasteride and dutasteride.
Used In Evidence Reviews
Similar Papers
Journal of the American Academy of Dermatology · 1998
Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Endocrine · 2017
Androgenetic alopecia: a review.
Journal of the American Academy of Dermatology · 2017
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Journal of cosmetic dermatology · 2021
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Expert opinion on pharmacotherapy · 2010
Male androgenetic alopecia.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2018